Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of bio-efficacy of field-aged novel long-lasting insecticidal nets (PBO, chlorfenapyr or pyriproxyfen combined with pyrethroid) against Anopheles gambiae (s.s.) in Tanzania.
Martin JL, Messenger LA, Bernard E, Kisamo M, Hape P, Sizya O, Festo E, Matiku W, Marcel V, Malya E, Aziz T, Matowo NS, Mosha JF, Mosha FW, Rowland M, Manjurano A, Protopopoff N. Martin JL, et al. Among authors: marcel v. Curr Res Parasitol Vector Borne Dis. 2024 Sep 23;6:100216. doi: 10.1016/j.crpvbd.2024.100216. eCollection 2024. Curr Res Parasitol Vector Borne Dis. 2024. PMID: 39399651 Free PMC article.
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response.
Tagnères S, Santo PE, Radermecker J, Rinaldi D, Froment C, Provost Q, Bongers M, Capeille S, Watkins N, Marcoux J, Gleizes PE, Marcel V, Plisson-Chastang C, Lebaron S. Tagnères S, et al. Among authors: marcel v. Nat Commun. 2024 Sep 27;15(1):8404. doi: 10.1038/s41467-024-52659-x. Nat Commun. 2024. PMID: 39333141 Free PMC article.
Antiviral Efficacy Testing of a Rechargeable Textile.
Izadjoo M, Carhart K, Marcel V, Izadjoo S, Swicegood F, Merritt C, Clarke G. Izadjoo M, et al. Among authors: marcel v. Mil Med. 2024 Aug 19;189(Supplement_3):525-529. doi: 10.1093/milmed/usae177. Mil Med. 2024. PMID: 39160886
Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
Paraqindes H, Mourksi NE, Ballesta S, Hedjam J, Bourdelais F, Fenouil T, Picart T, Catez F, Combe T, Ferrari A, Kielbassa J, Thomas E, Tonon L, Viari A, Attignon V, Carrere M, Perrossier J, Giraud S, Vanbelle C, Gabut M, Bergeron D, Scott MS, Castro Vega L, Magne N, Huillard E, Sanson M, Meyronet D, Diaz JJ, Ducray F, Marcel V, Durand S. Paraqindes H, et al. Among authors: marcel v. Neuro Oncol. 2023 Dec 8;25(12):2191-2206. doi: 10.1093/neuonc/noad140. Neuro Oncol. 2023. PMID: 37531290 Free PMC article.
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Mourksi NE, Dalban C, Colombe-Vermorel A, Odeyer L, Simioni V, Frenel JS, Fabbro M, Bazan F, Abadie-Lacourtoisie S, Coquan E, Martinez S, Garin G, Tabone-Eglinger S, Treilleux I, Chabaud S, Pérol D, Ray-Coquard I, Heudel PE, Diaz JJ, Marcel V. Mourksi NE, et al. Among authors: marcel v. Mol Oncol. 2023 Jan;17(1):27-36. doi: 10.1002/1878-0261.13340. Epub 2022 Dec 7. Mol Oncol. 2023. PMID: 36370117 Free PMC article.
snoDB 2.0: an enhanced interactive database, specializing in human snoRNAs.
Bergeron D, Paraqindes H, Fafard-Couture É, Deschamps-Francoeur G, Faucher-Giguère L, Bouchard-Bourelle P, Abou Elela S, Catez F, Marcel V, Scott MS. Bergeron D, et al. Among authors: marcel v. Nucleic Acids Res. 2023 Jan 6;51(D1):D291-D296. doi: 10.1093/nar/gkac835. Nucleic Acids Res. 2023. PMID: 36165892 Free PMC article.
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Heudel P, Frenel JS, Dalban C, Bazan F, Joly F, Arnaud A, Abdeddaim C, Chevalier-Place A, Augereau P, Pautier P, Chakiba C, You B, Lancry-Lecomte L, Garin G, Marcel V, Diaz JJ, Treilleux I, Pérol D, Fabbro M, Ray-Coquard I. Heudel P, et al. Among authors: marcel v. JAMA Oncol. 2022 Jul 1;8(7):1001-1009. doi: 10.1001/jamaoncol.2022.1047. JAMA Oncol. 2022. PMID: 35551299 Free PMC article. Clinical Trial.
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.
Nguyen Van Long F, Lardy-Cleaud A, Carène D, Rossoni C, Catez F, Rollet P, Pion N, Monchiet D, Dolbeau A, Martin M, Simioni V, Bray S, Le Beherec D, Mosele F, Bouakka I, Colombe-Vermorel A, Odeyer L, Diot A, Jordan LB, Thompson AM, Jamen F, Dubois T, Chabaud S, Michiels S, Treilleux I, Bourdon JC, Pérol D, Puisieux A, André F, Diaz JJ, Marcel V. Nguyen Van Long F, et al. Among authors: marcel v. BMC Cancer. 2022 May 11;22(1):526. doi: 10.1186/s12885-022-09552-x. BMC Cancer. 2022. PMID: 35545761 Free PMC article.
72 results